Can-Fite BioPharma Advances Clinical Trials for Psoriasis, HCC, and NASH
Key Insights
Can-Fite BioPharma focuses on orally bioavailable small molecule therapeutics for cancer, liver, and inflammatory diseases.
Piclidenoson is in Phase III clinical trials for psoriasis (search), showing promise in treating this chronic skin condition.
Namodenoson is progressing through Phase III trials for hepatocellular carcinoma (search) (HCC (search)) and Phase IIb for non-alcoholic steatohepatitis (search) (NASH (search)).
Can-Fite BioPharma Ltd. (CANF) is making significant strides in its clinical development programs, focusing on orally bioavailable small molecule therapeutics for cancer, liver, and inflammatory diseases. The company's pipeline features Piclidenoson, currently in Phase III trials for psoriasis (search), and Namodenoson, undergoing Phase III trials for hepatocellular carcinoma (search) (HCC (search)) and Phase IIb trials for non-alcoholic steatohepatitis (search) (NASH (search)).
Piclidenoson for Psoriasis
Piclidenoson, one of Can-Fite's leading drug candidates, is being evaluated in a Phase III clinical trial for the treatment of psoriasis (search). Psoriasis is a chronic autoimmune disease affecting millions worldwide, characterized by raised, scaly patches on the skin. The ongoing trial aims to assess the efficacy and safety of Piclidenoson in reducing psoriasis symptoms and improving patients' quality of life. The drug's oral bioavailability offers a convenient administration route, potentially enhancing patient compliance.
Namodenoson for Liver Diseases
Namodenoson is another key asset in Can-Fite's portfolio, targeting liver-related conditions. The drug is currently in a Phase III trial for hepatocellular carcinoma (search) (HCC (search)), the most common form of liver cancer. HCC is a major global health challenge with limited effective treatment options, underscoring the need for innovative therapies like Namodenoson. Additionally, Namodenoson is in a Phase IIb trial for non-alcoholic steatohepatitis (search) (NASH (search)), a serious liver condition characterized by liver inflammation and damage due to fat buildup. With the increasing prevalence of NASH and a lack of approved treatments, Namodenoson holds promise in addressing this unmet medical need.
A3 Adenosine Receptor (A3AR) Target
Can-Fite BioPharma utilizes its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (search) (A3AR), to develop its therapeutic candidates. This targeted approach allows for the development of selective and effective treatments for various diseases. The A3AR is involved in various physiological processes, including inflammation and cell growth, making it a promising target for therapeutic intervention.
Can-Fite BioPharma's commitment to improving patient outcomes through innovative therapeutic solutions is evident in its advanced clinical trials and strategic partnerships. The company's focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy. With its robust pipeline and targeted approach, Can-Fite BioPharma is poised to make a significant impact in the biopharmaceutical industry.